21 Sep 2014

ADP: Comprehensive Medical Conference Combines Experience to Improve Women’s Health

The Abu Dhabi Police Medical Services Department confirmed that the Comprehensive Medical Conference, which will be held in the next month, combines the expertise of local and international doctors. The Conference will contribute to the improvement of medical care for women and open new"...

Continue Reading

19 Sep 2014

Boehringer Ingelheim and CureVac Announce Collaboration to Develop Next Generation Lung Cancer Immunotherapy

  • Boehringer Ingelheim obtains exclusive global rights for development and commercialisation of CureVac’s investigational therapeutic cancer vaccine CV9202
  • CV9202 is based on CureVac’s mRNA technology (RNActive®)
  • Clinical investigation of CV9202 will be initiated in at least two different lung cancer treatment settings,...

    Continue Reading

16 Sep 2014

Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Shows Sustained Reduction in Blood Glucose in Phase III Study

Boehringer Ingelheim and Eli Lilly and Company today presented results from a 52-week Phase III study that demonstrated sustained efficacy of the investigational empagliflozin/linagliptin combination tablet in adults with type 2 diabetes (T2D) already taking metformin and in those who were"...

Continue Reading

10 Sep 2014

Egypt pledges support for Ebola fight

Egypt will provide medical supplies to Sierra Leone, Guinea and Liberia to help combat the threat of the Ebola virus that is sweeping through West African countries.

Egypt pledged medical supplies worth EGP 100,000 to Sierra Leone, EGP 150,000 to Guinea and EGP 150,000 to Liberia which will also receive an additional"......

Continue Reading

09 Sep 2014

Diabetes: Boehringer Ingelheim and Eli Lilly and Company announce data on portfolio to be presented at the 50th EASD Annual Meeting

  • 28 abstracts presented, including data on empagliflozin, an SGLT2 inhibitor recently approved in the European Union and in the US as Jardiance®
  • Abstracts on investigational empagliflozin/linagliptin combination tablet
  • Data on Lilly/BI’s investigational insulin glargine product
  • Abstracts on Trajenta® (linagliptin)...

    Continue Reading

08 Sep 2014

Asthma: new indication for Spiriva® (tiotropium) Respimat®* in the EU may offer millions of adults a significant advance in asthma care

  • Data show Spiriva® Respimat® reduced the risk of patients having a severe asthma exacerbation** by 21% when used as add-on therapy in patients who have symptoms despite taking current standard treatment†1
  • Almost one in two patients with asthma still experience symptoms while receiving current treatment options,2,3,4 putting...

    Continue Reading

08 Sep 2014

TONADO™ - further lung function and quality of life benefits with tiotropium + olodaterol Respimat® FDC* in COPD

European Respiratory Society International Congress 2014

  • First presentation of TONADO™ results for the only fixed-dose combination (FDC) containing tiotropium
  • Pivotal Phase III studies for tiotropium + olodaterol Respimat® FDC met lung function and quality of life"...

    Continue Reading

02 Sep 2014

ESC Congress 2014 Hot Line Session: Favourable effect of Pradaxa® on kidney function over time compared to warfarin

  • RE-LY® sub-analysis shows that Pradaxa® treatment favourably affects kidney function1 deterioration over time compared to warfarin
  • Data provide additional support for long-term use of Pradaxa® in stroke prevention in non-valvular atrial fibrillation (NVAF)1


Continue Reading

01 Sep 2014

Boehringer Ingelheim to Present Comprehensive Data Supporting Broad Respiratory Portfolio in COPD, Asthma and IPF at ERS 2014

  • First presentation of positive results from pivotal, Phase III TONADO™ studies that supported recent regulatory submissions in Europe and US for tiotropium + olodaterol Respimat®*in COPD - the only fixed-dose combination (FDC) containing tiotropium
  • Data further confirming role of Spiriva® in delivering long-term benefits to COPD patients...

    Continue Reading

01 Sep 2014

Extensive Experience in Clinical Practice and Expanding Research Programme Support use of Pradaxa® for Clot Prevention

  • Recent analysis of real world data document again the positive safety and efficacy profile of Pradaxa® as proven in clinical trials1-3
  • Final Phase of GLORIA™-AF Registry Program now initiated in North America and Europe
  • Extensive clinical research in established and new indications underway to improve patient care with Pradaxa®


Continue Reading
Found articles: 16 - Pages  1 2 
Contact US | Powered by - All Rights Reserved